Cargando…

Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results

BACKGROUND: Correct staging and grading of patients with clear cell renal cell carcinoma (cRCC) is of clinical relevance for the prediction of operability and for individualized patient management. As partial or radial resection with postoperative tumor grading currently remain the methods of choice...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, Lisa C., Bressem, Keno K., Jurmeister, Phillipp, Fahlenkamp, Ute L., Ralla, Bernhard, Engel, Guenther, Hamm, Bernd, Busch, Jonas, Makowski, Marcus R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555952/
https://www.ncbi.nlm.nih.gov/pubmed/31174616
http://dx.doi.org/10.1186/s40644-019-0222-8
_version_ 1783425243189084160
author Adams, Lisa C.
Bressem, Keno K.
Jurmeister, Phillipp
Fahlenkamp, Ute L.
Ralla, Bernhard
Engel, Guenther
Hamm, Bernd
Busch, Jonas
Makowski, Marcus R.
author_facet Adams, Lisa C.
Bressem, Keno K.
Jurmeister, Phillipp
Fahlenkamp, Ute L.
Ralla, Bernhard
Engel, Guenther
Hamm, Bernd
Busch, Jonas
Makowski, Marcus R.
author_sort Adams, Lisa C.
collection PubMed
description BACKGROUND: Correct staging and grading of patients with clear cell renal cell carcinoma (cRCC) is of clinical relevance for the prediction of operability and for individualized patient management. As partial or radial resection with postoperative tumor grading currently remain the methods of choice for the classification of cRCC, non-invasive preoperative alternatives to differentiate lower grade from higher grade cRCC would be beneficial. METHODS: This institutional-review-board approved cross-sectional study included twenty-seven patients (8 women, mean age ± SD, 61.3 ± 14.2) with histopathologically confirmed cRCC, graded according to the International Society of Urological Pathology (ISUP). A native, balanced steady-state free precession T2 mapping sequence (TrueFISP) was performed at 1.5 T. Quantitative T2 values were measured with circular 2D ROIs in the solid tumor portion and also in the normal renal parenchyma (cortex and medulla). To estimate the optimal cut-off T2 value for identifying lower grade cRCC, a Receiver Operating Characteristic Curve (ROC) analysis was performed and sensitivity and specificity were calculated. Students’ t-tests were used to evaluate the differences in mean values for continuous variables, while intergroup differences were tested for significance with two-tailed Mann-Whitney-U tests. RESULTS: There were significant differences between the T2 values for lower grade (ISUP 1–2) and higher grade (ISUP 3–4) cRCC (p < 0.001), with higher T2 values for lower grade cRCC compared to higher grade cRCC. The sensitivity and specificity for the differentiation of lower grade from higher grade tumors were 83.3% (95% CI: 0.59–0.96) and 88.9% (95% CI: 0.52–1.00), respectively, using a threshold value of ≥110 ms. Intraobserver/interobserver agreement for T2 measurements was excellent/substantial. CONCLUSIONS: Native T2 mapping based on a balanced steady-state free precession MR sequence might support an image-based distinction between lower and higher grade cRCC in a two-tier-system and could be a helpful addition to multiparametric imaging. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40644-019-0222-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6555952
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65559522019-06-10 Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results Adams, Lisa C. Bressem, Keno K. Jurmeister, Phillipp Fahlenkamp, Ute L. Ralla, Bernhard Engel, Guenther Hamm, Bernd Busch, Jonas Makowski, Marcus R. Cancer Imaging Research Article BACKGROUND: Correct staging and grading of patients with clear cell renal cell carcinoma (cRCC) is of clinical relevance for the prediction of operability and for individualized patient management. As partial or radial resection with postoperative tumor grading currently remain the methods of choice for the classification of cRCC, non-invasive preoperative alternatives to differentiate lower grade from higher grade cRCC would be beneficial. METHODS: This institutional-review-board approved cross-sectional study included twenty-seven patients (8 women, mean age ± SD, 61.3 ± 14.2) with histopathologically confirmed cRCC, graded according to the International Society of Urological Pathology (ISUP). A native, balanced steady-state free precession T2 mapping sequence (TrueFISP) was performed at 1.5 T. Quantitative T2 values were measured with circular 2D ROIs in the solid tumor portion and also in the normal renal parenchyma (cortex and medulla). To estimate the optimal cut-off T2 value for identifying lower grade cRCC, a Receiver Operating Characteristic Curve (ROC) analysis was performed and sensitivity and specificity were calculated. Students’ t-tests were used to evaluate the differences in mean values for continuous variables, while intergroup differences were tested for significance with two-tailed Mann-Whitney-U tests. RESULTS: There were significant differences between the T2 values for lower grade (ISUP 1–2) and higher grade (ISUP 3–4) cRCC (p < 0.001), with higher T2 values for lower grade cRCC compared to higher grade cRCC. The sensitivity and specificity for the differentiation of lower grade from higher grade tumors were 83.3% (95% CI: 0.59–0.96) and 88.9% (95% CI: 0.52–1.00), respectively, using a threshold value of ≥110 ms. Intraobserver/interobserver agreement for T2 measurements was excellent/substantial. CONCLUSIONS: Native T2 mapping based on a balanced steady-state free precession MR sequence might support an image-based distinction between lower and higher grade cRCC in a two-tier-system and could be a helpful addition to multiparametric imaging. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40644-019-0222-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-07 /pmc/articles/PMC6555952/ /pubmed/31174616 http://dx.doi.org/10.1186/s40644-019-0222-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Adams, Lisa C.
Bressem, Keno K.
Jurmeister, Phillipp
Fahlenkamp, Ute L.
Ralla, Bernhard
Engel, Guenther
Hamm, Bernd
Busch, Jonas
Makowski, Marcus R.
Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results
title Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results
title_full Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results
title_fullStr Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results
title_full_unstemmed Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results
title_short Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results
title_sort use of quantitative t2 mapping for the assessment of renal cell carcinomas: first results
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555952/
https://www.ncbi.nlm.nih.gov/pubmed/31174616
http://dx.doi.org/10.1186/s40644-019-0222-8
work_keys_str_mv AT adamslisac useofquantitativet2mappingfortheassessmentofrenalcellcarcinomasfirstresults
AT bressemkenok useofquantitativet2mappingfortheassessmentofrenalcellcarcinomasfirstresults
AT jurmeisterphillipp useofquantitativet2mappingfortheassessmentofrenalcellcarcinomasfirstresults
AT fahlenkamputel useofquantitativet2mappingfortheassessmentofrenalcellcarcinomasfirstresults
AT rallabernhard useofquantitativet2mappingfortheassessmentofrenalcellcarcinomasfirstresults
AT engelguenther useofquantitativet2mappingfortheassessmentofrenalcellcarcinomasfirstresults
AT hammbernd useofquantitativet2mappingfortheassessmentofrenalcellcarcinomasfirstresults
AT buschjonas useofquantitativet2mappingfortheassessmentofrenalcellcarcinomasfirstresults
AT makowskimarcusr useofquantitativet2mappingfortheassessmentofrenalcellcarcinomasfirstresults